# Does FDG PETCT have a predictive value for neoadjuvant chemotherapy response in nonmetastatic breast cancer?

## TL;DR

This study explores whether FDG PETCT SUVmax can predict response to neoadjuvant chemotherapy in early-stage breast cancer.

## Contribution

The study identifies baseline PETCT SUVmax as an independent predictor of pathological complete response to neoadjuvant chemotherapy.

## Key findings

- High SUVmax group showed a trend toward higher pCR rates, though not statistically significant.
- Baseline PETCT SUVmax was found to be an independent predictive factor for pCR (p = 0.025).

## Abstract

A pathological complete response (pCR) rate after neoadjuvant chemotherapy (NAC) is important for the prognosis of early-stage breast cancer. The prediction of an NAC response plays a key role in managing neoadjuvant treatment.

The aim of this study is to investigate the predictive value of the baseline PETCT FDG (F-18 fluoro-deoxy-glucose (FDG) positron emission tomography/computed tomography) SUVmax (the maximum standardized uptake value) for pCR after NAC in early-stage breast cancer.

The patients who performed PETCT before NAC were included in this retrospective study. The basal PETCT SUVmax values were divided into two categories based on the cutoff points of ≥ 8.77 or < 8.77, namely the low SUV max group and the high SUV max group. These two groups were compared according to the general characteristics. The impact of the PETCT SUVmax values on pCR was determined with logistic regression analyses.

One hundred forty-eight patients who performed PETCT before NAC were included in this retrospective study. Eighty-one patients were in the low SUV max group and 67 patients were in the high SUVmax group. The pCR trended toward a higher rate in the high SUVmax group than in low SUVmax group but it was not statistically significant (p = 0.052). The baseline PETCT SUVmax value was an independent predictive factor for pCR. (p = 0.025).

PETCT SUVmax may be a factor for the predicting complete response to neoadjuvant treatment in early-stage breast cancer.